Exploring the potential of immunotherapy in early-stage triple-negative breast cancer

Triple-negative breast cancers, which are more frequently diagnosed in younger women, are a subtype of breast tumor characterized by the absence of hormone receptors and HER2 overexpression. As a result, they do not respond to hormone therapy or HER2-targeted treatments. Their prognosis is generally less favorable than that of other breast cancer subtypes.

≈